-

Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”) announces the closing of its previously announced private placement of units of the Company for gross proceeds of US$1,345,093 before deducting the placement agent’s fees and other offering expenses payable by the Company. Pursuant to the closing, the Company issued a total of 6,114,058 units at a price of US$0.22 per unit. Each unit consists of a common share and a half warrant, with each whole warrant entitling the holder to purchase an additional common share at a price of $0.31 for a period of three years. All dollar amounts are in US dollars.

The Company also announces that it will be continuing a best efforts private placement offering of units (the “New Units”) at a price of US$0.22 per unit for aggregate gross proceeds of up to US$5.2 million (the “Continued Offering”). Each New Unit will consist of one common share and one half of one warrant, with each whole warrant entitling the holder to purchase an additional common share at a price of US$0.31 for a period of three years from the issuance date.

The Company expects to use the net proceeds from the private placement for research and development, general and administrative matters, and working capital. The Company may complete additional closings pursuant to the private placement.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) or any state securities laws, and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.

Contacts

Michael McFadden, CEO
Tel: 1-858-344-4375
info@alphacognition.com
https://www.alphacognition.com/

Alpha Cognition Inc.

CNSX:ACOG

Release Versions

Contacts

Michael McFadden, CEO
Tel: 1-858-344-4375
info@alphacognition.com
https://www.alphacognition.com/

Social Media Profiles
More News From Alpha Cognition Inc.

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its fourth quarter and full year financial results and business highlights o...

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP), taking place April 16-20, 2026 and the Neuroscience Education Institute (NEI) Spring Congress, taking place May 1-3, 2026. The...

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting. The BEACON study is designed to assess the real-world imp...
Back to Newsroom